Last reviewed · How we verify
NCT03282253
Elevated Stearoyl-CoA Desaturase-1 Expression Predicts the Disease Severity of Severe Acute Pancreatitis
trial in Acute Pancreatitis in 216 participants. Status unknown.
30 December 2018
Quick facts
| Lead sponsor | Nanjing University School of Medicine |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 216 |
| Start date | 1 January 2018 |
| Primary completion | 30 December 2018 |
| Estimated completion | 30 June 2019 |
Conditions studied
- Acute Pancreatitis — all drugs for Acute Pancreatitis →
- Organ Failure, Multiple — all drugs for Organ Failure, Multiple →
Sponsor
Nanjing University School of Medicine
Who can join
Adults 18 to 75, any sex, with Acute Pancreatitis or Organ Failure, Multiple. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investgatiors aimed to investigate the associations between serum levels of stearoyl-CoA desaturase-1（SCD-1） and the disease severity as well as the presence of adverse clinical events, such as local complications, organ failure, mortality and so on.In this prospective study, participants were divided into two groups based on serum SCD-1 concentration on admission and prospectively observe the disease severity and clinical outcomes of them.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Role of Oleic Acid in the Gut-Liver Axis: From Diet to the Regulation of Its Synthesis via Stearoyl-CoA Desaturase 1 (SCD1).
Piccinin E, Cariello M, De Santis S, Ducheix S, et al · · 2019 · cited 109× · PMID 31554181 · DOI 10.3390/nu11102283
Verify or expand the search:
- PubMed search for NCT03282253
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Pancreatitis
Currently open trials in the same condition.
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT06899087 — DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis · recruiting
- NCT07322978 — Incidence of Splanchnic Venous Thrombosis in Acute Pancreatitis and it's Correlation With Severity of Pancreatitis · recruiting
- NCT03547232 — Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial) · Phase 4 · recruiting
- NCT06401577 — Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics · recruiting
Other Nanjing University School of Medicine trials
Trials by the same sponsor.
- NCT06285279 — The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases · Phase 1 · recruiting
- NCT06226896 — Effects of Dapagliflozin on Progression of Alport Syndrome · active not recruiting
- NCT05863936 — Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis · Phase 3 · unknown
- NCT06376214 — Daratumumab for Patients With Light Chain Amyloidosis · NA · recruiting
- NCT04507945 — Stablishment of Prevention and Treatment System for Intestinal Dysfunction · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03282253 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing University School of Medicine
- Last refreshed: 27 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03282253.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing